Abstracts

Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100

Background Sotorasib, a specific, irreversible KRAS G12C inhibitor, is approved in multiple countries for adults with KRAS p.G12C-mutated locally advanced or metastatic NSCLC who have re...

07/02/2022

Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib: Subanalysis of BEACON CRC

Background Although the majority of colorectal cancer (CRC) diagnoses occur in adults ≥50 years old (y), there has been a rise in CRC diagnoses in adults BRAF V600E-mutant metastatic CRC...

Eric Van Cutsem , MD, PhD;

07/02/2022

Clinical efficacy and single-cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

Background While combinations of BRAF inhibitors with EGFR and/or MEK inhibitors have improved efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and durability is ...

07/02/2022

Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC

Background Despite the occurrence of HER2 amplification/overexpression (HER2+) in ∼3% to 5% of all patients with metastatic colorectal cancer (mCRC) and up to ∼10% of patients with RAS/B...

Eric Van Cutsem , MD, PhD;

07/02/2022

Background The AtezoTRIBE study demonstrated that the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab prolongs PFS of mCRC patients, but a clinically modest benefit was obse...

Kirk McGregor ;

F. Bergamo ;

S. Leonetti ;

L. Provenzano ;

S. Tamberi ;

M. Ramundo ;

Giampaolo Tortora ;

C. Antoniotti ;

C. Rasola ;

A. Boccaccino ;

D. Ross ;

V. Conca ;

T. Nielsen ;

M. Giordano ;

M. Varga ;

C. Cremolini ;

A. Passardi ;

R. Seitz ;

M. Ambrosini ;

L. Salvatore ;

07/02/2022

T-cell abundance measured by immunoSEQ predicts overall survival in colorectal cancer

Background Tumor infiltrating lymphocytes measured by expert pathologists are an independent prognostic factor for colorectal cancer. Newer PCR-based techniques to quantify T-cells withi...

07/02/2022

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset

Background Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are oncogenic drivers in various tumour types. Larotrectinib is a first-in-class, highly selective tropomyosin rece...

Jordan D. Berlin ;

C. Mussi ;

D. Oh ;

Serge Leyvraz ;

A. Drilon ;

Maria de Miguel ;

Yongmei Liu ;

Marc Fellous ;

Lin Shen ;

Thierry André , MD;

Elena Garralda ;

Aitana Ferrandiz ;

D. Hong ;

Jyoti Patel ;

J. Deeken ;

R. Xu ;

Dae Ho Lee ;

A. Italiano ;

Hyun Cheol Chung ;

T. Liu ;

Ichiro Kinoshita ;

R. Norenberg ;

07/02/2022

Neoadjuvant immunotherapy in gastrointestinal tumors with mismatch repair deficiency: An institutional analysis

Background Clinical trials have reported robust anti-tumor activity of immunotherapy (IO) in metastatic deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) solid tu...

07/02/2022

Entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis

Background Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions, coding for constitutively active chimeric tyrosine receptor kinase (TRK) proteins, are oncogenic drivers found in ...

07/02/2022

Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC)

Background The BRAF V600E mutation is associated with the hypermethylator phenotype CIMP, which can also lead to the MSI-H phenotype. BRAF V600E mutation and MSI-H/dMMR status seem to be...

Eric Van Cutsem , MD, PhD;

07/02/2022